Ascend Biopharmaceuticals reports favourable outcomes from TG1042 Phase 2 research for CBCL treatment Ascend Biopharmaceuticals, a Melbourne-based immunotherapy organization, has today announced the publication of a report utilising TG1042 for the treating Cutaneous B-Cell Lymphoma , in the journal PLOS A single. Ascend Biopharmaceuticals entered into a special world-wide license contract with Transgene in July of 2013 to develop TG1042 as an immunotherapeutic injection for multiple cancers including Cutaneous B-Cell Lymphoma, CBCL . Ascend plans to sponsor and commence clinical studies with TG1042 in Basal Cell Carcinoma later in 2014 here .
Ascent Healthcare Solutions introduces CE credit programs for sustainable healthcare solutions Ascent Healthcare Solutions, a leader in delivering healthcare resource sustainability, today launched an on the web educational portal on its Web site offering complimentary accredited Ongoing Education programs. The first available applications are made to teach simple, impactful practices for increasing sustainability in the functioning EP and room lab. Developed in response to overwhelming industry demand for even more education on sustainability methods, these first courses are tailored to all or any hospital-based registered nurses, technicians and administrators.